Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • FIRST: Roche wins DCGI...

    FIRST: Roche wins DCGI nod for Atezolizumab to treat small-cell lung cancer

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 22 Nov 2019 6:55 AM  |  Updated On 16 Aug 2021 7:32 AM

    "Atezolizumab is the first cancer immunotherapy to receive approval from DCGI in India for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) when given in combination with chemotherapy," Roche India said in a statement.


    New Delhi: Drug firm Roche India on Thursday said it has launched Atezolizumab used for the treatment of small-cell lung cancer in India after getting a nod from Drugs Controller General of India.


    "Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC) when given in combination with chemotherapy," Roche India said in a statement.


    The cancer immunotherapy harnesses the person's immune system to combat cancer more effectively for better results, it added.


    Read Also: CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug

    "Roche is committed to bringing to India all the innovations being developed in its pipeline, to benefit patients," Lara Bezerra, chief purpose officer at Roche Products (India) said. Launching Atezolizumab is an important step for small cell lung cancer patients in India, she added.


    Read Also: Roche Tecentriq, Avastin combo to increase overall survival, progression-free survival in HCC

    atezolizumabcancercancer immunotherapyDCGIDrugs Controller General of IndiaOncologRocheSCLCsmall-cell lung cancer
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok